About TBC1 domain family member 9B
TBC1 domain family member 9B (TBC1D9B) is a protein
from Homo sapiens identified by UniProt accession
Q66K14, 1250 residues long.
MolForge cross-references it against 0 known binders and
53 disease associations.
Target properties
| Protein name | TBC1 domain family member 9B |
|---|
| UniProt accession | Q66K14 |
|---|
| Gene | TBC1D9B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1250 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (53)
Diseases linked to this target (Open Targets).
- aspartate aminotransferase measurement · score 0.28
- serum albumin measurement · score 0.24
- brain volume measurement · score 0.20
- leukocyte count · score 0.17
- mathematical ability · score 0.15
- neutrophil percentage of leukocytes · score 0.08
- viral load · score 0.07
- neutrophil count · score 0.07
- appendicular lean mass · score 0.06
- hemoglobin E-beta-thalassemia syndrome · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q66K14-F1 | alphafold | PREDICTED | 74.26 | — |
Amino-acid sequence (1250 residues)
MWLSPEEVLV ANALWVTERA NPFFVLQRRR GHGRGGGLTG LLVGTLDVVL DSSARVAPYR ILHQTQDSQV YWTVACGSSR KEITKHWEWL ENNLLQTLSI FDSEEDITTF VKGKIHGIIA EENKNLQPQG DEDPGKFKEA ELKMRKQFGM PEGEKLVNYY SCSYWKGRVP RQGWLYLTVN HLCFYSFLLG KEVSLVVQWV DITRLEKNAT LLFPESIRVD TRDQELFFSM FLNIGETFKL MEQLANLAMR QLLDSEGFLE DKALPRPIRP HRNISALKRD LDARAKNECY RATFRLPRDE RLDGHTSCTL WTPFNKLHIP GQMFISNNYI CFASKEEDAC HLIIPLREVT IVEKADSSSV LPSPLSISTK SKMTFLFANL KDRDFLVQRI SDFLQKTPSK QPGSIGSRKA SVVDPSTESS PAPQEGSEQP ASPASPLSSR QSFCAQEAPT ASQGLLKLFQ KNSPMEDLGA KGAKEKMKEE SWHIHFFEYG RGVCMYRTAK TRALVLKGIP ESLRGELWLL FSGAWNEMVT HPGYYAELVE KSTGKYSLAT EEIERDLHRS MPEHPAFQNE LGIAALRRVL TAYAFRNPTI GYCQAMNIVT SVLLLYGSEE EAFWLLVALC ERMLPDYYNT RVVGALVDQG IFEELTRDFL PQLSEKMQDL GVISSISLSW FLTLFLSVMP FESAVVIVDC FFYEGIKVIL QVALAVLDAN MEQLLGCSDE GEAMTMLGRY LDNVVNKQSV SPPIPHLRAL LSSSDDPPAE VDIFELLKVS YEKFSSLRAE DIEQMRFKQR LKVIQSLEDT AKRSVVRAIP VDIGFSIEEL EDLYMVFKAK HLASQYWGCS RTMAGRRDPS LPYLEQYRID ASQFRELFAS LTPWACGSHT PLLAGRMFRL LDENKDSLIN FKEFVTGMSG MYHGDLTEKL KVLYKLHLPP ALSPEEAESA LEAAHYFTED SSSEASPLAS DLDLFLPWEA QEALPQEEQE GSGSEERGEE KGTSSPDYRH YLRMWAKEKE AQKETIKDLP KMNQEQFIEL CKTLYNMFSE DPMEQDLYHA IATVASLLLR IGEVGKKFSA RTGRKPRDCA TEEDEPPAPE LHQDAARELQ PPAAGDPQAK AGGDTHLGKA PQESQVVVEG GSGEGQGSPS QLLSDDETKD DMSMSSYSVV STGSLQCEDL ADDTVLVGGE ACSPTARIGG TVDTDWCISF EQILASILTE SVLVNFFEKR VDIGLKIKDQ KKVERQFSTA SDHEQPGVSG
Explore TBC1 domain family member 9B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets